-
Product Insights
NewBlood Glucose Meters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Blood Glucose Meters Pipeline Market Report Overview A blood glucose meter is an electronic diabetic management device used for measuring blood glucose levels. Additionally, continuous glucose monitors are covered under this segment. The blood glucose meters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799544 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799544 in Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799544 in Brain Tumor Drug Details: PF-07799544 (ARRY-134) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS) Drug Details: Pitolisant...
-
Product Insights
NewQuarterly Cheese pricing trends in Ukraine
Empower your strategies with our Quarterly Cheese pricing trends in Ukraine report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important business choices....
-
Product Insights
Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Fragile X Syndrome Clinical Trial Report Overview A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Sector Analysis
Switzerland Renewable Energy Policy Handbook, 2024 Update
Switzerland Renewable Energy Policy Overview The Electricity Supply Act (ESA) of Switzerland is the primary act for electricity, which guarantees the supply of electricity and security of supply also, specifies the legal basis for the electric grid. In February 2014, the Swiss Federal Office of Energy (SFOE) began revising the ESA to bring it into harmony with the 2050 Energy Strategy. Furthermore, the Swiss government introduced the Energy Strategy 2050 in 2007 and it forms the major policy in the...
-
Product Insights
NewNet Present Value Model: Harmony Biosciences Holdings Inc’s Zygel
Empower your strategies with our Net Present Value Model: Harmony Biosciences Holdings Inc's Zygel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Triple-Negative Breast Cancer (TNBC) Drug Details: CX-072...
-
Thematic Analysis
Net Zero Strategies in the Mining Sector – Thematic Intelligence
Reasons to buy the ‘Net Zero Strategies in the Mining Sector’ thematic intelligence report: Gain in-depth insight into the net zero targets and performance of key mining companies. Elucidate the importance of a net zero strategy in the mining sector. Analyze the progress made by the leading companies within the theme to achieve their emission target. Analyze the net zero strategies in the mining sector theme to develop effective business plans and gain a competitive edge. How is our ‘Net...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...